タイプ2糖尿病:グローバル医薬品市場予測・分析(~2022)...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 19
1.2 List of Figures 27
2 Introduction 29
2.1 Catalyst 29
2.2 Related Reports 30
3 Disease Overview 31
3.1 Etiology and Pathophysiology 31
3.1.1 Etiology 31
3.1.2 Pathophysiology 32
3.1.3 Prognosis 33
3.1.4 Quality of Life 34
3.2 Symptoms 34
4 Epidemiology 36
4.1 Risk Factors and Comorbidities 36
4.1.1 Family history of diabetes is a strong predictor of type 2 diabetes 37
4.1.2 The risk of type 2 diabetes increases dramatically around age 50 38
4.1.3 The risk of developing type 2 diabetes increases as BMI increases 39
4.1.4 Gestational diabetes increases the risk of developing type 2 diabetes later in life up to 10 times 40
4.1.5 Up to 75% of adults with type 2 diabetes have hypertension 41
4.1.6 Nearly all type 2 diabetics also have dyslipidemia 42
4.2 Global Trends 43
4.2.1 US 43
4.2.2 5EU 47
4.2.3 Japan 50
4.2.4 Brazil 52
4.2.5 China and India 52
4.3 Forecast Methodology 54
4.3.1 Sources Used 57
4.3.2 Forecast Assumptions and Methods 67
4.3.3 Sources Not Used 76
4.4 Epidemiology Forecast of Type 2 Diabetes (2012-2022) 77
4.4.1 Prevalent Cases of Diagnosed Type 2 Diabetes 77
4.4.2 Age-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 79
4.4.3 Sex-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 81
4.4.4 Age-Standardized Prevalence of Diagnosed Type 2 Diabetes 83
4.4.5 Overweight/Obesity among Diagnosed Prevalent Cases of Type 2 Diabetes 84
4.4.6 Hypertension among Diagnosed Prevalent Cases of Type 2 Diabetes 86
4.4.7 Dyslipidemia among Diagnosed Prevalent Cases of Type 2 Diabetes 88
4.5 Discussion 89
4.5.1 Limitations of the Analysis 92
4.5.2 Strengths of the Analysis 93
5 Disease Management 95
5.1 Treatment Overview 95
5.1.1 Diagnosis and Referrals 95
5.1.2 Treatment Guidelines 96
5.2 US 102
5.2.1 Diagnosis 102
5.2.2 Clinical Practice 102
5.3 France 103
5.3.1 Diagnosis 103
5.3.2 Clinical Practice 103
5.4 Germany 104
5.4.1 Diagnosis 104
5.4.2 Clinical Practice 104
5.5 Italy 106
5.5.1 Diagnosis 106
5.5.2 Clinical Practice 107
5.6 Spain 109
5.6.1 Diagnosis 109
5.6.2 Clinical Practice 109
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 112
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 114
5.9 China 115
5.9.1 Diagnosis 115
5.9.2 Clinical Practice 116
5.10 India 117
5.10.1 Diagnosis 117
5.10.2 Clinical Practice 117
5.11 Brazil 118
5.11.1 Diagnosis 118
5.11.2 Clinical Practice 118
6 Competitive Assessment 119
6.1 Overview 119
6.2 Strategic Competitor Assessment 120
6.3 Product Profiles – Major Brands 122
6.3.1 Metformin 122
6.3.2 Sulfonylureas (SUs) and Other Insulin Secretagogues 127
6.3.3 α-glucosidase Inhibitors (AGIs) 133
6.3.4 Thiazolidinediones (TZDs) 137
6.3.5 GLP-1 Receptor Agonists 142
6.3.6 DPP-4 Inhibitors 165
6.3.7 SGLT-2 Inhibitors 194
6.3.8 Insulin Formulations 204
7 Opportunity and Unmet Need 231
7.1 Overview 231
7.2 Unmet Needs 232
7.2.1 Drugs Providing Sustained Glycemic Control 232
7.2.2 Drugs with Non-Glycemic Benefits 233
7.2.3 Increased Patient Compliance 234
7.2.4 Drugs with Improved Side-Effect Profiles 235
7.2.5 Earlier Diagnosis 236
7.3 Unmet Needs Gap Analysis 237
7.4 Oral Therapy with Sustainable Efficacy 238
7.5 Oral Therapy Offering Weight Loss 238
7.6 Cardio-metabolic Therapy 239
7.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 239
8 Pipeline Assessment 240
8.1 Overview 240
8.2 Clinical Trial Mapping 241
8.2.1 Clinical Trials by Country 241
8.3 Clinical Trials by Phase and Trial Status 242
8.4 Promising Drugs in Clinical Development 244
8.4.1 Albiglutide 248
8.4.2 Dulaglutide (LY2189265) 254
8.4.3 Semaglutide 261
8.4.4 Trelagliptin (SYR-472) 266
8.4.5 MK-3102 270
8.4.6 Empagliflozin 275
8.4.7 Tofogliflozin 281
8.4.8 Ipragliflozin 286
8.4.9 LY2409021 291
8.4.10 LY2605541 (insulin peglispro) 296
9 Current and Future Players 302
9.1 Overview 302
9.2 Trends in Corporate Strategy 305
9.3 Company Profiles 306
9.3.1 Eli Lilly 306
9.3.2 Bristol-Myers Squibb 309
9.3.3 Novo Nordisk 313
9.3.4 Sanofi 316
9.3.5 GlaxoSmithKline 318
9.3.6 AstraZeneca 320
9.3.7 Merck & Co 322
9.3.8 Boehringer Ingelheim 324
9.3.9 Takeda 326
9.3.10 Roche 329
9.3.11 Pfizer 330
9.3.12 Johnson & Johnson 332
10 Market Outlook 334
10.1 Global Markets 334
10.1.1 Forecast 334
10.1.2 Drivers and Barriers – Global Issues 339
10.2 US 340
10.2.1 Forecast 340
10.2.2 Key Events 345
10.2.3 Drivers and Barriers 346
10.3 France 348
10.3.1 Forecast 348
10.3.2 Key Events 352
10.3.3 Drivers and Barriers 353
10.4 Germany 355
10.4.1 Forecast 355
10.4.2 Key Events 359
10.4.3 Drivers and Barriers 360
10.5 Italy 361
10.5.1 Forecast 361
10.5.2 Key Events 365
10.5.3 Drivers and Barriers 366
10.6 Spain 367
10.6.1 Forecast 367
10.6.2 Key Events 371
10.6.3 Drivers and Barriers 372
10.7 UK 374
10.7.1 Forecast 374
10.7.2 Key Events 378
10.7.3 Drivers and Barriers 379
10.8 Japan 381
10.8.1 Forecast 381
10.8.2 Key Events 385
10.8.3 Drivers and Barriers 386
10.9 China 388
10.9.1 Forecast 388
10.9.2 Key Events 392
10.9.3 Drivers and Barriers 393
10.10 India 395
10.10.1 Forecast 395
10.10.2 Key Events 399
10.10.3 Drivers and Barriers 399
10.11 Brazil 402
10.11.1 Forecast 402
10.11.2 Key Events 406
10.11.3 Drivers and Barriers 406
11 Appendix 410
11.1 Bibliography 410
11.2 Abbreviations 442
11.3 Methodology 445
11.4 Forecasting Methodology 445
11.4.1 Diagnosed Type 2 Patients 446
11.4.2 Percent Drug-Treated Patients 446
11.4.3 Drugs Included in Each Therapeutic Class 446
11.4.4 Launch and Patent Expiry Dates 447
11.4.5 General Pricing Assumptions 448
11.4.6 Individual Drug Assumptions 449
11.4.7 Generic Erosion 458
11.4.8 Pricing of Pipeline Agents 458
11.5 Physicians and Specialists Included in this Study 460
11.6 About the Authors 462
11.6.1 Analyst II – CVMD 462
11.6.2 Therapy Director – CVMD and Infectious Disease 462
11.6.3 Senior Epidemiologist 463
11.6.4 Global Head of Healthcare 463
11.7 About GlobalData 464
11.8 Disclaimer 464


【レポート販売概要】

■ タイトル:タイプ2糖尿病:グローバル医薬品市場予測・分析(~2022)
■ 英文:PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
■ 発行日:2014年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC76PIDR
■ 調査対象地域:グローバル
  • バサルト繊維の世界市場
    The basalt fiber market size is projected to grow at a significant double digit CAGR between 2015 and 2020. Major growth in the Asia-Pacific region is expected from the growing building & construction, automotive and wind turbine blades application. The basalt fiber market in Asia-Pacific region is growing fast as the application industries such as growing building & construction, automotive and w …
  • ソーシャルBI(ビジネス・インテリジェンス)ソリューションの世界市場
    About Social Business Intelligence Social media is a business tool helps organizations to create and maintain the visibility and their brand image to their customers. Social media provides wide range of services, communications, and feedbacks which in turn helps to understand the customer demands and needs. In this process social media networks generate huge volume of data from diverse sources and …
  • 航空機シート作動システムの世界市場2016-2020
    About Commercial Aircraft Seat Actuation Systems Aircraft seat actuation systems provide comfortable seating for the passengers in commercial aircraft and private jets. The automated systems allow passengers to adjust their seating position as per their comfort level. The seat actuators are an essential component of aircraft cabins in a modern aircraft. With designs to provide correct seating posi …
  • ヘッドアップディスプレイ(HUD)の世界市場2016-2020
    About Heads-Up Display An HUD is a display indicator that displays key flight information on a transparent screen positioned in front of the pilot's line of sight. The automotive and aviation are the major application sectors for HUDs because they increase situational awareness and enhance safety margins. The primary components of HUDs are combiner, projector unit, display panel, video generator. …
  • 1型糖尿病治療薬の世界市場2016-2020
    About Type 1 Diabetes Drugs Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types: • Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels. • Type 2 diabetes (non-insulin-dependen …
  • グローバル画像診断装置(医療機器)メーカー分析(技術能力、戦略、課題):Hitachi
    The strategic assessment of Hitachi, one of the world's leading diagnostic imaging companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The new report from Venture Planning Group presents a comprehensive analysis of the company's performance, capabilities, goals, and strategies in t …
  • 第Ⅸ因子欠乏症治療の世界市場2017-2021
    ABSTRACTAbout Factor IX Deficiency Treatment The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of …
  • モデルマウスの世界市場分析・予測(~2021):近交系モデルマウス、ノックアウトモデルマウス、雑種モデルマウス
    The mice model market is expected to reach USD 1.59 Billion in 2021 from USD 1.11 Billion in 2016, growing at a CAGR of 7.5%. Ongoing innovations in mice models, personalized medicine driving the demand for humanized mice models, continuous support in the form of investments and grants, and growing pharmaceutical R&D activities are some of the factors that are expected to drive the growth of the g …
  • 血管ガイドワイヤーの世界市場2016-2020
    About Vascular Guidewires Vascular guidewires are used in interventional procedures in guiding the catheters to target specific site for treatment. The growing older population is a major contributor to the growth of the market. WHO estimates that about two billion people will be aged 60 and above by 2050. The older adult population is susceptible to chronic diseases, and thus requires frequent ca …
  • グローバル国土安全保障市場におけるトップ10企業分析
    Synopsis The Strategic Defence Intelligence Global Top 10 Homeland Security Contractors: Company Guide is a crucial resource for anyone looking to gain information on the top companies in the global homeland security industry. Detailed company profile and SWOT analysis information is provided for all the leading companies who are ranked in order by total annual revenues generated. International Bu …
  • 教育用ロボットの世界市場2016-2020
    About the Educational Robots Market The benefits of technology across different industries has led the education industry to become adopt the latest and most-suitable technologies to enhance teaching delivery and learning experience. With advances in technology, robotics has been successfully integrated into various sectors. Industrial robots have replaced the manual workload in many industries wh …
  • メキシコの風力発電市場2016:発電能力、生産、投資動向、制度、企業
    Wind Power in Mexico, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles Summary "Wind Power in Mexico, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles” is the latest report from GlobalData, the industry analy …
  • てんかん発作重積状態(Status Epilepticus)の治療薬パイプライン動向(2015年上半期版)
    Status Epilepticus - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Status Epilepticus - Pipeline Review, H1 2015’, provides an overview of the Status Epilepticus’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mecha …
  • 木材接着剤の世界市場分析:製品別(尿素 – ホルムアルデヒド、メラミン尿素、フェノール – ホルムアルデヒド、イソシアネート、ポリウレタン、PVA、大豆ベース)、用途別(床材、家具、ドア、窓)、セグメント予測、2014-2025
    The global wood adhesives market is expected to reach USD 6.18 billion by 2025, according to a new report by Grand View Research, Inc. Recovery in the global housing market and increasing consumer spending on luxury furniture and home décor has prompted higher investments in lightweight and convenient bonding materials such as wood adhesives.The demand for timber furniture and plywood building mat …
  • 二分脊髄(脊髄披裂)治療のグローバル臨床試験動向(2014年下半期)
    Spina Bifida Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Spina Bifida Global Clinical Trials Review, H2, 2014" provides data on the Spina Bifida clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spina Bifida. It includes an overview of the trial numbers and their recruitment status as per the sit …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。